Characterization of the BRAF interactome identifies BRAF V600E <=>TP53 interaction in melanoma
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Melanoma is a highly aggressive and frequently metastatic cancer with its incidence reported to be on the rise. Although most oncogenic drivers in melanoma converge on activation of the RAS>RAF>MEK>ERK MAPK signaling pathway, not all MAPK-activating mutations are recurrently observed in this disease, suggesting a unique functional role for BRAF V600E , which is present in ∼50% of all melanoma cases. However, the prevalence of BRAF V600E alterations over other known MAPK-promoting oncoproteins raises questions regarding whether BRAF V600E possesses additional functions outside of MAPK pathway activation. Thus, we performed TurboID to differentiate the interactome between wild-type BRAF and BRAF V600E . We identified novel interacting partners of normal vs. BRAF V600E , most strikingly being the tumor suppressor TP53. While TP53 is commonly altered or lost across many malignancies, it is notable that TP53 alterations are rare in melanoma. Our studies suggest that BRAF V600E can interact with and inactivate TP53, thus providing potential mechanistic explanation as to why TP53 inactivation or loss is infrequent in BRAF V600E -driven melanoma.
